comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 01:08:26 - browse：388

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

knowledge

WSS

UnitedHealth’s board chair also owns a personal investment firm

Explaining an after

The health care issue Democrats can’t solve: hospital reform

Humans aren't the only ones with an imagination. Rats have it too

Researchers explore possible ties between long Covid, menopause

Eli Lilly expects to double planned employment in Boston center

Wikipedia

comprehensive

hotspot

Heart attack and stroke risk calculators need revising

Senate committee scrutinizes Medicare Advantage brokers

Psychedelics group wrestles with new pharma identity

FDA struggles to regulate food additives, sometimes for decades

DIEP, the 'gold standard' of breast reconstruction, is under threat

The health care issue Democrats can’t solve: hospital reform

Hollywood unions extend contract negotiations for actors

Key Senate panel to consider PBM, drug pricing reform package

Dobbs anniversary: the lost opportunity of abortion as health care

DeepMind touts AlphaFold's new skills as protein folding AI models face off

explore

Bill would allow buprenorphine prescription for addiction via telehealth

Solve the antibiotic resistance crisis with preventive drugs

NIH confirmation hearing shows politicization of research

Hospital price transparency does save money, advocate argues

NIH confirmation hearing shows politicization of research

Infant mortality in U.S. rose last year for first time in decades: CDC

entertainment

leisure time

knowledge

focus